CNS cancer immunity cycle and strategies to target this for glioblastoma. by Ameratunga, M et al.
CNS Cancer Immunity Cycle and strategies to target this for glioblastoma 
Authors  
 
Malaka	Ameratunga1,	Niamh	Coleman1,	Liam	Welsh1,	Frank	Saran1,	Juanita	Lopez1	
	
Affiliations:	
1Royal	Marsden	Hospital		
Downs	Rd,	Sutton		
London		
SM2	5PT	
	
Correspondence:	
juanita.lopez@icr.ac.uk	
	
Keywords:	
Glioblastoma,	immunotherapy,	cancer-immunity	cycle,	checkpoint	inhibitors,	clinical	trials.	
  
 
Abstract 
Immunotherapeutics have revolutionized the management of solid malignancies over the last 
few years.  Nevertheless, despite relative successes of checkpoint inhibitors in numerous 
solid tumour types, success in tumours of the central nervous system (CNS) has been 
lacking. There are several possible reasons for the relative lack of success of 
immunotherapeutics in this setting, including the immune microenvironment of glioblastoma, 
lymphocyte tracking through the blood-brain barrier (BBB) into the central nervous system 
and impairment of drug delivery into the CNS through the BBB.  This review utilizes the 
cancer-immunity cycle as a conceptual framework through which the specific challenges 
associated with the development of immunotherapeutics for CNS malignancies can be 
viewed. 
 
  
Introduction:  
The recent development of immune checkpoint inhibitors and the corresponding efficacy 
shown by inhibitors of the CTLA-4-B7 (1) and PD-1/PD-L1 checkpoints (2-7) in multiple 
tumour types has resulted in substantial investment by the pharmaceutical industry in clinical 
development of immunotherapeutics across tumour types and indications.  Although, in 
particular, the efficacy of inhibitors of the PD-1/PD-L1 checkpoint has been consistent across 
tumour types, the single agent activity of these drugs has been lacking in tumours of the 
central nervous system (CNS).  In particular, several studies have shown less promising 
results in glioblastoma compared with other tumour types (8, 9). Glioblastoma, however, 
poses unique challenges to the immunotherapy treatment paradigm, as traditionally the CNS 
has been regarded as an immune-privileged site (10); the frequent concomitant 
administration of immunosuppressive medications such as corticosteroids in this patient 
population is an additional consideration.   Although these recent trials have cast doubts 
over the role, if any, of immunotherapeutics in CNS malignancies, they may also serve as an 
opportune time to evaluate the nuances of the emerging biology surrounding the cancer-
immunity cycle and the specific challenges relating to drug development in primary brain 
tumours. 
 
The cancer-immunity cycle was first proposed by Chen and Mellman (11) as a paradigm for 
the interaction between the immune system and cancer.  They argue that a series of step-
wise events must occur for effective anti-tumour immunity and coined the cycle to describe 
these events.  Cancer cells and cancer cell death initially results in the release of 
neoantigens, which are then presented to dendritic cells. Priming and activation 
subsequently occurs, leading to trafficking of T cells to tumours, and subsequent infiltration 
of effector cells into tumours. There is then recognition of cancer cells by effector T cells, 
which results in cancer cell death which reiterates the cycle.  This review evaluates the 
challenges of developing successful immunotherapeutics for glioblastoma through the lens 
of the cancer-immunity cycle.  We initially describe the current understanding of the immune 
system in the central nervous system and subsequently address unique aspects of the 
immune system in the brain.  We then describe current clinical development of CNS 
immunotherapeutics and the relative lack of efficacy of immune checkpoint inhibition to date.  
Finally we provide a conceptual framework through which the development of effective 
immunotherapeutic strategies in the CNS can be viewed, and specific considerations for 
clinical trial design for CNS immunotherapeutics. 
 
The immune system and the brain – biological challenges and immune privilege 
Historically, the CNS has been considered an immune-privileged site for a triumvirate 
number of reasons (12). Firstly, histological absence of observable lymphatics disputed 
lymphatic circulation in the brain, theoretically impeding functional immunity. Secondly, the 
blood-brain barrier (BBB) has been a major limitation since it was first described by Paul 
Elrlich in the late 19th century (13). The BBB comprises a physical barrier due to complex 
tight junctions between adjacent endothelial cells, which requires transcellular passage of 
molecules trafficking into brain tissue compared to typical paracellular trafficking in other 
tissue sites (14).  Practically this results in limited penetration of antibodies, immune 
mediators and immune cells through the BBB from the systemic circulation into the CNS 
(15). The third pillar of immune privilege was the disparity between the CNS immune system 
compared to the rest of the body, “apparent immune absence”, supported by observations 
such as the paucity of dendritic cells in the brain parenchyma (16), the seminal work of 
Lampson demonstrating the lack of major histocompatibility complex (MHC) class I on 
neuronal and glial tissue, the relative paucity of MHC class II expression in resections of 
brain tumour patients (17) and the  tight regulation of the expression of T cell co-stimulatory 
molecules within the brain (18). A large body of emerging work is now challenging the 
traditional assumptions underlying this concept of relative CNS immune privilege with good 
evidence indicating that the CNS is both immune competent and actively interacts with the 
peripheral immune system.    
 
Challenging lymphatic circulation as a pillar of immune privilege 
Firstly, we now have clear evidence of lymphatic circulation within the brain (19).  Louveau 
and colleagues used sensitive imaging techniques to neatly show that the cerebrospinal fluid 
circulation leads to lymphatic drainage of the brain via the cervical and nasal lymphatics (20) 
suggesting that immune cells and tumour antigens may pass through the cerebrospinal fluid 
to the draining cervical lymphatics to meet with the antigen processing and presenting 
machinery and thereby stimulating the development of a systemic immune anti-tumour 
response (Figure 1). Although naive antigen-inexperienced T cells tend not to enter the 
healthy CNS and remained located in perivascular, subarachnoid, or meningeal spaces (24), 
activated CNS-specific CD4+ T cells are able to apparently chaperone naive non-CNS-
specific T cells across the BBB into the CNS (25).   
Challenging the BBB as a pillar of immune privilege 
Importantly, it is increasingly recognised that the BBB is dynamic, with its phenotype 
developing from complex cell-cell interactions from adjacent astrocytes (14, 26) and with its 
permeability varying based upon the functional requirements of signalling systems in the 
brain.  For instance the fenestrated endothelial wall at the hypothalamus allows diffusion of 
hormones into the systemic circulation, whereas the absence of the BBB at the area 
postrema allows relative free perfusion of molecules from the blood into brain tissue (13).  Of 
particular relevance in brain tumours, the tight junctions of the BBB can be disrupted in the 
setting of cerebral oedema (27), pro-inflammatory cytokines, such as interferon-γ and tumor 
necrosis factor-α (13), anatomical disruption from direct tumour extension, as well as 
downregulation of tight junction proteins such as claudins 1,3 (14) (28).   These observations 
gel with histopathological findings in brain tumour series, which have consistently 
demonstrated significant quantities of infiltrating immune cells in glioblastoma specimens, 
both macrophages but also CD4+ and CD8+ lymphocytes (29), as well as dynamic markers 
of the immune response such as PD-L1 (30).  Taken together, these factors demonstrate 
that the BBB is a relative rather than an absolute barrier, when considering implications for 
the trafficking of immune cells or the delivery of cancer therapeutics.   
 
Challenging apparent immune absence as a pillar of immune privilege 
Finally, although there are definite difference in the immune system of the brain compared to 
other sites, this does not definitively preclude functional CNS immunity.  Systemically, it is 
widely recognised that the critical components of the antitumour immune response are 
cytotoxic T cells and the adaptive immune system, and that overactivation of the innate 
immune system can paradoxically promote tumorigenesis (31).  Nevertheless, some degree 
of innate immune activation is a requisite for functional anticancer immunity.  Critical 
components of the systemic anticancer immune response include immune recognition cells 
such as dendritic cells, immune effector cells such as cytotoxic CD8+ T cells and the 
supporting apparatus of CD4+ helper T cells.   In the brain, microglia serve as the functional 
antigen presenting cells, having been shown by sensitive assays to avidly express MHC 
class II molecules, particular in the setting of inflammation, and are now thought to be able to 
directly present tumour antigens to T cells within the brain  (21-23).  Although preclinical 
models of healthy mice suggested that the CNS parenchyma lacks a potent innate immune 
response (32), resident microglia are able to recognize “pathogen associated molecular 
patterns” and “danger associated molecular patterns”, which include heat shock proteins, 
uric acid, high-mobility group box 1 protein (HMGB1), and other structures available during 
tissue damage, inflammation and cell death (33). Heat shock proteins released from tumor 
cells may be particularly effective chaperones for tumor-specific peptide antigens and may 
both activate dendritic cells and serve as antigen couriers (34, 35).  Thus there appears to 
be sufficient innate immune system activation in the CNS to generate an antitumour immune 
response. 
 
It has been challenging to identify how the innate immune system activates the adaptive 
antitumour immune response in the brain, but preclinical models suggests that activated 
dendritic cells carry antigens and transit to the cervical lymph nodes where a systemic 
immune response is stimulated (36). Additionally CNS-derived soluble tumour antigens may 
directly drain to the lymphatics where they are presented by peripheral antigen-presentation 
machinery (37) .  
A CNS-specific T-cell trafficking programme is yet to be identified, but preclinical work in 
auto-immune murine models suggests that activation of T cells within the cervical lymph 
nodes have a direct role for the neuro-inflammation seen (38). Three potential immune entry 
sites into the CNS have been described, localizing to the superficial leptomeningeal vessels, 
parenchymal vessels and the choroid plexus (39). In agreement with these findings, immune 
cell infiltrates are found in tumor tissue derived from brain cancers consisting of both 
macrophages and CD4+ and CD8+ lymphocytes (29, 40).  Furthermore, antibodies are able 
to penetrate into the CNS, albeit at lower concentrations than in the systemic circulation (41), 
providing evidence of the humoral component of the adaptive immune system in the brain.  
These factors suggest that there is a functional cellular and humoral immune response in the 
brain, the key components of which are demonstrated in Figure 1.  Counteracting this 
functional adaptive immunity is the increasing recognition of a particularly 
immunosuppressive tumour microenvironment in the archetypal primary CNS tumour, 
glioblastoma. 
 
The immunosuppressive tumour microenvironment of glioblastoma has been well 
documented  (42) and characterized by the myriad anti-inflammatory cytokines secreted by 
glioma cells. Cytokines such as tumor growth factor-β (TGF-β), interleukin (IL)-6, IL-10 and 
prostaglandin E2 actively suppress the expression of MHC on microglia, thereby limiting 
antigen presentation and diminishing the cytotoxic T cell response (43, 44). The infiltrating T 
cell population is over-represented by regulatory T cells (Tregs) (45), which are regulated by 
factors such as the enzyme indoleamine 2,3-dioxygenase (IDO) (46) and serve functionally 
in brain tumors to suppress the immune system (47). This diminished response is further 
exacerbated by the promotion of the alternative M2 macrophage phenotype in glioblastoma 
(48).  There is a substantial body of literature demonstrating that phenotype switching of 
tumour-associated macrophages from M1 to M2 promotes tumorigenesis in diverse ways 
(48). In glioblastoma, the presence of M2 macrophages has been correlated with increasing 
histological grade, which is thought to be driven in some part by tumoral expression of 
macrophage colony-stimulating factor (45, 49).  Thus, the development of clinically 
efficacious immunotherapeutics in the brain has to both consider the unique aspects of the 
CNS immune system and the historical pillars of immune privilege as well as offsetting 
contribution of the immunosuppressive microenvironment in glioblastoma. 
 
Current clinical developments in CNS immunotherapeutics 
The use of the PD-1/PD-L1 immune checkpoint inhibitors to unleash the T cell response  has 
been most studied immunotherapeutic strategy in glioblastoma, but has proved mostly 
disappointing in single agent studies presented thus far (8, 50, 51)  (Table 1). Checkmate-
143 was a Phase 3 study exploring nivolumab in comparison to bevacizumab in the setting 
of recurrent glioblastoma and demonstrated a tolerability profiles consistent with 
observations in other tumor types. Disappointingly however, CheckMate-143 did not meet its 
primary endpoint of improved overall survival, as presented by Reardon et al at World 
Federation of Neurooncology Societies  2017 with lower documented response rates in the 
nivolumab arm in spite of a hint of more durable responses in the responding patients (8, 
52).   
Registration 
number 
Treatment Overall response rate* 
(%), (N) 
Comments 
 
NCT02017717 
Nivolumab 8% (n=153) (8) Longer duration of response 
(11.1 mo compared to 5.3 
mo for bevacizumab). 
Median PFS 1.5 mo. 
12 month OS 42%. 
 
NCT02054806 
Pembrolizumab 
 
4% (n=26) (53) Median OS 14.4 mo. 
Median PFS 2.8 mo. 
 
NCT02336165 Durvalumab 
 
13.3% (n=31) (9) 
 
12 month OS 44.4% 
6 month OS 59.0% 
6 month PFS 20.0% 
* Overall response rate according to RANO criteria 
PFS- progression-free survival 
OS- overall survival 
 
Table 1: Reported results of single agent checkpoint inhibitors trials in recurrent 
glioblastoma 
 
Of note however, are the case reports of therapeutic successes in specific pediatric patients 
with biallelic mismatch repair deficiencies (54) suggesting that these antibodies do cross the 
BBB and penetrate into the tumour microenvironment, and are able to release a tumour 
specific cytotoxic T cell response. Given that these patients have hypermutated tumours with 
significantly high mutational load and therefore a significant immunogenic burden and thus a 
larger repertoire of tumor antigen-specific T cells  (55, 56), the inclusion of a selected subset 
of glioma patients with high mutational burden into clinical trials of checkpoint inhibitors is 
one strategy currently being pursued (for example, in NCT02628067).  As a population 
however, the mutational load in primary malignant brain tumours is low, approximately 10-
fold lower than in melanoma and lung cancer (57, 58) with the mutational load  being 
associated with tumour grade (59).  And although the currently available standard treatments 
of radiation and temozolomide are themselves mutagenic (60), and one may extrapolate that 
in cells that survive, the neoantigen load is likely to rise, thereby diversifying epitopes 
available for recognition by T cells, this has been insufficient in isolation to stimulate an 
adaptive immune response as demonstrated by the limited sensitivity to single agent 
immune checkpoint inhibition in the recurrent setting (Table 1). As such, consideration of 
other nodes in the CNS immunity cycle to be targeted with combinatorial strategies are 
urgently needed and discussed in detail in the following sections (Figure 2).  
 
The CNS cancer-immunity cycle- a framework for immunotherapeutic strategies in 
CNS tumour 
 
Cancer Cell Death- DNA damaging agents and immunogenic cell death  
Initiaiting the cancer immunity cycle is cell death and immunogenic cell death refers to 
activation of the immune system by apoptotic cells or pre-apoptotic cells resulting in tumor 
cell death (61).  DNA damaging agents including radiation and temozolomide can cause 
immunogenic cell death and the release of danger signals including “damage-associated 
molecular patterns” that stimulate the recruitment of APCs where they process and present 
tumour neoantigens, thereby priming an adaptive immune response (62). It is worth noting 
that to date there does not appear to be any evidence that immunogenic cell death is 
affected by mutational load (62). In preclinical murine glioma models, combined PD-1 
blockade and stereotactic radiosurgery (SRS) have been shown to improve antitumor 
immunity and produce long-term survivors (63, 64) and this concept is now in early clinical 
testing in patients with malignant brain tumours. The focus on augmenting immunogenic cell 
death in glioblastoma to negate the limited single agent efficacy of PD-1 inhibition is 
translating into ongoing early phase clinical trials.  Sahebjam et al recently presented 
preliminary findings from one such phase I study evaluating the concomitant use of 
hypofractionated SRS, pembrolizumab, and bevacizumab for recurrent, high-grade gliomas 
noting that all patients tolerated the regimen, and and an impressive durable response rate 
(response for ≥ 6 months) of 53% was noted (65, 66). Numerous other combination trials of 
immunotherapy in combination with DNA damaging agents for CNS malignancies are 
ongoing including with temozolomide (e.g. NCT02311920), radiotherapy (NCT02617589, 
NCT02336165) and the combination of temozolomide and radiation (NCT02667587).  
 Antigen presentation- oncolytic Virotherapy and vaccine strategies 
Cell death can kickstart the cancer-immunity cycle in the brain by activating the adaptive 
immune system via antigen presentation.  There are several complementary therapeutic 
strategies that are focussing upon this component of the cancer-immunity cycle in the the 
brain.  Oncolytic virotherapy makes use of non-pathogenic viruses to selectively invade or 
specifically express proteins in brain tumor cells that can directly kill cancer cells or 
otherwise stimulate an immune response, therefore marrying both the concepts of 
immunogenic cell death with antigen presentation. The oncolytic polio virus utilizes the 
aberrant expression of the poliovirus receptor, CD155, in solid tumours to mediate viral cell 
entry (67).  In humans, infection of tumor macrophages and dendritic cells is sublethal and 
eventually leads to induction of MHC class II expression and the stimulation of a tumor 
antigen-specific T cell response (67) (68). A Phase I clinical trial of a poliovirus chimera, 
PVSRIPO for recurrent glioblastoma produced overall showed that this approach was safe, 
with initial promising results, with 10 out of the initial 13 patients treated still alive at the end 
of the trial (69). To overcome the attenuated immune responses within the brain, groups are 
attempting to engineer virotherapy with inducible inflammatory cytokines, for example the 
Ad-RTS-hIL-12, an inducible adenoviral vector that expresses IL12 in the presence of an 
orally-administered activator ligand, veledimex. This early phase trial showed evidence of 
systemic increases of IL-12, IFNγ as well as increased number of CD8+T-cells in circulation, 
with an impressive 100% 6-month survival for the 13 patients thus far (70). The challenge 
here is that virotherapy for brain tumors relies heavily on viral migration to the tumor site and 
has mostly been explored by intratumoural injection which is not always achievable. Efforts 
are therefore underway to explore the feasibility of systemic intravenous delivery approaches 
to overcome this (e.g. REOGLIO ISRCTN70044565). 
 
Apart from tumour cell lysis mediated by oncolytic viruses, there are complementary 
methods of targeting antigen presentation in the brain.  In particular, the identification of a 
growing number of potentially unique immunoreactive tumor-associated antigens expressed 
by human gliomas make cancer vaccines including peptide, dendritic cell, tumor cell, and 
neoantigen vaccines a very exciting strategy. Moreover, this approach can be utilized 
peripherally, bypassing the logistically challenges of delivering therapeutics directly 
intracranially. Peptide vaccines induce a T-cell response at the tumor site by releasing 
peptides specific to tumor-associated antigens. These are commonly coupled with carrier 
proteins and adjuvants, are taken up by APCs and presented on the cell surface by MHC 
molecules. APCs navigate the lymphatic system to prime T-cells, which then recognize the 
tumor cell from its antigen (71). Glioblastoma represents an attractive therapeutic target for 
peptide vaccination as the unique epidermal growth factor receptor (EGFR) variant, 
EGFRvIII,is expressed in approximately 30% of patients with glioblastoma (72).  The most 
advanced therapeutic candidate peptide vaccine  is rindopepimut, which targets a 
neoepitope created by a 13 amino-acid sequence unique to EGFRvIII, chemically 
conjugated to KLH which serves as an immune adjuvant (73).  Although initially heralded as 
a major breakthrough on the back of positive early phase studies (74), recent published 
large phase three studies have failed to show a survival benefit and argue against 
rindopepimut’s efficacy (75), and this may be largely due to the heterogenous nature of 
glioblastoma.  To address this issue of heterogeneously-expressed tumor-associated 
antigens, multi-peptide vaccine strategies such as the IMA950 vaccine which contains 11 
human leukocyte antigen (HLA)-restricted tumor-associated peptides are being explored 
with some initial hints of benefit, particularly in a sub-group of patients with marked injection 
site reactions (76). Other candidate peptide vaccines are also showing initial promise in early 
phase clinical trials (77, 78) and the results of larger studies are eagerly waited.   
The alternative vaccine strategy is of dendritic cell vaccination. Instead of injecting a peptide 
that is presented to an APC, autologous dendritic cells sourced from peripheral blood 
monocytes are primed with tumour lysate from the patients’ own tumour in the presence of 
growth factors such as interleukin-4 and granulocyte macrophage colony stimulating factor, 
(79). Immature dendritic cells can uptake and process tumour-associated antigens, and 
mature ex vivo, thus becoming capable of proper antigen presentation for T-cell recognition 
in a MHC-restrictive manner (80). These pools of dendritic cells are subsequently 
autologously transplanted into patients. Studies performed in glioblastoma patients have 
typically involved injection intradermally (79, 81) in proximity to the draining cervical lymph 
nodes, or occasionally in patients with Ommaya reservoirs, directly into the cerebrospinal 
fluid (81).  In these studies, although unarguable clinical benefit could not be observed, there 
was clear evidence of increases in tumour-lysate specific T cells in the periphery (81) and 
tumour lysate specific memory T cells and cytotoxic T cells intratumorally (79).  One 
example is the ICT-107 autologous dendritic cell vaccine pulsed with six tumor-associated 
antigens for which ten-year follow-up data is available for the initial Phase I vaccine trial. 
19% of 16 patients remained disease free for 8 years with a median overall survival of 38.4 
months (82). These durable responses have fueled combination studies with checkpoint 
inhibitors which are ongoing (for example NCT02529072).   
 
T cell activation 
Antigen presentation is followed by T cell activation in the cancer immunity cycle, which 
represents another potentially target of immunotherapeutic strategies in the brain.  The 
inhibitory cell surface protein CLTA4 primarily regulates the amplitude of the early stages of 
T cell activation (83) and is expressed solely by T-cells localized primarily within secondary 
lymphoid tissues. It binds preferentially to CD80/CD86 on the surface of APCs, thus 
preventing their binding to the T-cell co-stimulatory receptor CD28, leading to decreased T-
cell activation and proliferation in the context of antigen-presenting MHC class (84-87). 
CTLA-4 also contributes to immune modulation by enhancing the suppressor functions of 
Tregs (88). 
 
The combination of anti-CTLA-4 plus anti-PD-1 has demonstrated encouraging activity in 
preclinical murine models of orthotopic transplanted gliomas(45, 63, 64, 89, 90), however 
this has failed to translate substantial clinical benefit (8). In the Phase I CheckMate-143 
study, 90% of patients who received combination therapy had grade 3 or 4 treatment-related 
adverse events , and 50% of patients in that arm had to discontinue treatment early due to 
intolerability leading to the exclusion of this combination in the subsequent phase II/III study 
(52).  In patients with an overall poor prognosis, this limited efficacy combined with 
significant toxicity is unacceptable and as such, needs tweaking to deliver tangible clinical 
benefits to patients.  One approach to minimize the risk of increased systemic toxicity from 
these combination is to use intra-tumoral delivery of anti-CTLA-4 following the resection of 
the recurrent glioblastoma which is currently ongoing (NCT03233152).  
 
Lymphocyte-trafficking into the CNS: BBB 
Following T cell activation, the CNS cancer immunity cycle needs to consider trafficking into 
the CNS and crossing the BBB.  The therapeutic strategy most advanced in glioblastoma 
that may theoretically affect the BBB is anti-angiogenic therapy.  Although, initially uptake of 
anti-angiogenics was met by optimism due to unprecedented response rates (91), 
subsequent large randomised trials have failed to demonstrate evidence of benefit (92) (93) 
and a large meta-analysis has shown no overall survival benefit for these agents (94).  
Nevertheless, emerging data support a strong rationale for combining therapies targeting 
vessel normalization with immunotherapies (95).  In particular, abnormal tumour vasculature 
promotes the production of cytokines which preferentially recruit immunosuppressive 
lymphoid populations (95) and polarize tumor associated macrophages to the 
immunosuppressive M2 phenotype (48). As such, combinations of anti-angiogenics together 
with checkpoint inhibitors are actively being pursued in early phase clinical trials 
(NCT02336165, NCT02337491).  It is however, worth noting that glioblastoma is a highly 
invasive tumour, and that anti-angiogenic agents may paradoxically promote invasiveness 
(96, 97) thus impeding the efficacy of this combination. 
 
Other ingenious out-of-the-box solutions are being explored to overcome the impediment of 
the BBB in drug delivery. Armed with the knowledge that some of the activity of radiotherapy 
in brain tumours is due to disruption of tight junctions and therefore vessel permeability (98), 
the hypotheses that low dose radiotherapy could increase drug delivery to the CNS was 
recently tested (99). Preliminary results in a cohort of resected brain metastases patients 
has demonstrated substantially (~20x) higher tissue afatinib concentrations compared to 
plasma, thereby validating this hypothesis.  Other viable strategies to disrupt the BBB 
undergoing clinical evaluation include the combination of microbubble injections with pulsed 
ultrasound, which has been shown to functionally disrupt the BBB on serial contrast-
enhanced MRI (100).  These trials provide proof-of-principle that augmentation of drug 
delivery into the CNS could be achieved and is likely to be used in combination strategies in 
the near future.  
 
 
Infiltration and recognition of tumour- adoptive cell therapy 
Once lymphocytes have been trafficked to the tumour, the effector components of the 
immune system have to infiltrate into the tumour and recognise the tumour to propagate the 
CNS cancer immunity cycle.  One strategy targeting this component of the cycle is adoptive 
cell therapy.  Instead of relying on the afferent of the neuro-immune system, adoptive cell 
therapy aims to engineer and directly activate T cells which are then able to home back to 
the tumour (Figure 2). This technology, first developed by Gross et al (101) (CAR) utilizes a 
chimeric construct consisting of a single-chain variable fragment of a high affinity antibody 
recognizing a tumour antigen fused to one/multiple co-stimulatory domains that directly 
activate T cells (CART) in a non-MHC restricted manner (101) They have exhibited striking 
activity in hematological malignancies and the first CART therapy recently being approved 
by the FDA for use in relapsed B cell precursor acute lymphoblastic leukemia (102).  Efforts 
in solid tumours are ongoing (see Table 2), but suffer from lack of well described cell surface 
targets which are solely expressed on tumour cells and absent from normal tissue (103). In 
some ways, glioblastoma is relatively fortunate compared to other solid malignancies, with 
the well described truncating EGFRvIII variant (72) exhibiting characteristics of an opportune 
target – high frequency aberration in target disease and absence in normal tissue.  
Consequently, CART cells targeting this variant are undergoing clinical development (104). 
The first-in-human Phase I study of CART-EGFRvIII cells demonstrated the safety of this 
approach, without evidence of off-target toxicity or cytokine release syndrome with one 
patient having stable disease at 18 months (105).  
 
Other antigens being targeted in current clinical trials include Eph-A2 and IL13Rα2 (see 
Table 2). Preliminary results from a Phase I trial of a first-generation CART cells targeting 
the glioblastoma tumor antigen IL13Rα2 reported safe intracranial delivery of the CART-cells 
with one particular patient exhibiting a 79% regression of recurrent tumour mass  (106). 
Building on this, a 2nd generation CART incorporating a 4-1BB (CD137) costimulatory 
domain and a mutated IgG4-Fc linker to reduce off-target Fc-receptor interaction is in testing 
with a dramatic transient clinical response in a patient with recurrent multifocal glioblastoma 
(107). Two important lessons can be drawn from this study – firstly, the challenge of T cell 
homing as this patient did not respond to the initial intercavitary delivery of CART cells, but 
responded dramatically when this was switched to an interventricular mode of delivery. And 
secondly, despite the incredible radiological response, the patient relapsed with tumours that 
had significantly decreased IL13Rα2 expression suggesting that antigenic heterogeneity 
may be a significant hurdle to the success of this approach. Technical advances in cellular 
engineering may help overcome some of these challenges, for example a recent preclinical 
study has shown that trivalent CART cells targeting commonly expressed glioma antigens 
including HER-2, IL13Rα2 and Eph-A2 can overcome tumour heterogeneity and target 
nearly all tumour cells in patient-derived xenograft models compared to bispecific or single-
epitope targeting CARs (108).   
  
NCT number Tumour type Target Mode of delivery 
NCT02331693 Advanced Glioma EGFR Systemic infusion (IV) 
NCT02209376 Glioblastoma Multiforme EGFRvIII Systemic infusion (IV) 
NCT02844062 Glioblastoma Multiforme EGFRvIII Systemic infusion (IV) 
NCT01454596 Glioblastoma Multiforme EGFRvIII 
Systemic infusion with 
aldesleukin (IL-2) (IV) 
NCT02937844 Glioblastoma Multiforme PD-L1 
Systemic infusion (three-
day split) (IV) 
NCT02575261 Glioma EphA2  Systemic infusion (IV) 
NCT02664363 Glioblastoma Multiforme EGFRvIII 
Systemic infusion (IV) 
Companion imaging 
study. 
NCT01082926 Brain tumours IL13Rα2 Intratumoral 
NCT02208362 High grade glioma IL13Rα2 Intratumoral 
NCT02442297 Glioblastoma Multiforme Her2 Intratumoral 
NCT01109095 Glioblastoma Multiforme 
Her2 (CMV specific T 
cells) 
Systemic infusion (IV) 
 
Table 2: Ongoing trials of CART cells in glioblastoma   
 
Overcoming the suppressive immune microenvironment 
Finally, for ongoing cell death to perpetuate the CNS cancer immunity cycle, the 
immunosuppressive microenvironment must be overcome.  The challenge of the 
immunosuppressive microenvironment has been particularly highlighted by the early phase 
CART trials. O’Rourke and colleagues found evidence of trafficking of CART-EGFRvIII cells 
to regions of active glioblastoma, with antigen decrease in five of these seven patients who 
proceeded to surgery, but in all cases in situ evaluation of the tumour microenvironment 
demonstrated increased and robust expression of inhibitory molecular and infiltration by 
regulatory T cells after CART-EGFRvIII infusion, compared to pre-infusion specimens (105). 
As such, novel strategies targeting  the immune microenvironment are urgently required. 
Components of the immunosuppressive microenvironment include Tregs, monocytes as well 
as signaling molecules, all of which could theoretically be targeted to enhance anti-cancer 
immunity in glioblastoma. 
In particular, given the prominence of the M2 macrophage phenotype in glioblastoma (49), 
strategies aiming to switch macrophage polarization are being explored. Preclinical models 
implicate the macrophage colony stimulating factor 1 receptor (CSF-1R) in 
macrophage/monocyte polarization to the pro-tumorigenic M2 phenotype and antagonists to 
this are in clinical testing (NCT02526017). Other signaling molecules including the 
phosphoinositide 3-kinase (PI3K) signaling pathway also have a role in directly polarization 
of macrophages to the M2 phenotype (109) and despite limited single agent activity of 
multiple PI3K pathway inhibitors in glioblastoma (110), these may have value 
combinatorially.   
TGFβ, secreted by tumour cells in an autocrine loop is a potent immunosuppressive cytokine 
and inhibits the efficacy of immune effector cells (111).  A bispecific antibody targeting PD-
L1 and TGFβR2 has shown preclinical evidence of enhancing antibody-dependent cellular 
cytotoxicity mediated by both PD-L1 and TGFβR2 preclinically (111) and is now in clinical 
trials including a glioma cohort of patients (112) (NCT02517398). Other ongoing trials 
include combinations with the TGFβR1 inhibitor galunersertib (NCT02423343).  
 
The immunoregulatory enzyme IDO has been heavily associated with immune tolerance 
(113) and has been specifically associated with controlling the functional status of Tregs in 
response to inflammatory stimuli (46).  Inhibitors of this enzyme are amongst the most 
advanced novel immunotherapeutics in clinical development with multiple clinical trials 
ongoing in numerous tumour types including in glioblastoma (NCT02052648).  Although 
single agent activity of IDO inhibitors have not been promising in solid tumours (114), recent 
reports of significantly higher response rates in combination with PD-1 inhibitors have 
prompted excitement (115) and this strategy may have utility in combinations for 
glioblastoma.  
 
Cancer immunity 
cycle component 
Possible therapeutic strategy Examples of current trials  
Cell death • Combination with DNA 
damaging agents 
• Combination with 
stereotactic radiosurgery 
• NCT02311920, 
NCT02617589, 
NCT02336165 
NCT02667587 
• NCT02313272 
Antigen presentation • Oncolytic viruses 
• Vaccines 
• ISRCTN70044565 
• NCT02529072 
T cell activation • Intratumoural CTLA-4 
combination 
• NCT03233152 
Lymphocyte trafficking • Combination with 
antiangiogenic agents 
• NCT02336165, 
NCT02337491 
Infiltration and 
recognition of tumour 
• CART cells/ adoptive cell 
therapy 
• NCT02209376 
Overcoming the 
suppressive immune 
microenvironment 
• Macrophage polarization 
• Bispecific antibodies 
• Immunoregulatory 
inhibitors 
• NCT02526017 
• NCT02517398 
• NCT02052648 
 
Table 3: Current strategies targeting the cancer-immunity cycle in glioblastoma 
 
Considerations for CNS drug development 
In this review, we have presented a framework for understanding the CNS-cancer immunity 
cycle in order to effectively develop immunotherapeutics for CNS tumours. Table 3 
summarises the components of the cancer immunity cycle and current strategies targeting 
these components.  Rational strategies backed by strong preclinical data for combinations 
must be developed in order to optimize efficacy.  In particular, specific challenges unique to 
brain tumours must be considered.  One of the major hurdles in developing preclinical 
insights is the lack of biologically relevant models for hypothesis testing.  Moreover, although 
in other solid tumours sequential tumour biopsies are increasingly used to compress clinical 
development timelines and improve pharmacodynamic studies (116), given the relative 
importance of brain tissue and associated difficulty with tissue sampling, this strategy is 
simply not feasible in CNS tumours.  Nevertheless, there are ways to combat this specific 
issue.  In particular, having optional research biopsy components in patients who are 
undergoing re-resections for clinical reasons can bypass this problem.  Pharmacokinetic 
information can also be established with cerebrospinal fluid samples, which has previously 
added useful information to pharmacokinetic profiles (117).  
 
Other specific challenges unique to the CNS include the aforementioned BBB, which is an 
impediment to effective CNS penetration of numerous drugs.  There are a number of 
approaches that that may mitigate this problem.  Firstly, a number of trials are currently 
being performed on small molecule inhibitors, with the compound being delivered 
immediately in the pre-operative period prior to re-resection, thus allowing for a more 
substantial study of pharmacodynamic endpoints.  Secondly, given a substantial component 
of the cancer-immunity cycle occurs peripherally, there is no reason why therapeutics 
targeting the periphery cannot have central activity.   
 
There are also some unique clinical considerations in glioblastoma patients that can impede 
effective drug delivery and drug development.  Many patients with brain tumours have 
uncontrolled seizures requiring numerous anti-epileptic medications.  These represent a 
challenge in early phase clinical trials, as typically the use of such drugs is prohibited due to 
the uncertain pharmacokinetic profiles that they result in, particularly in the development of 
drugs predicted to be metabolized by the hepatic cytochrome p450 system.  However, it is 
important to note that second and third generation anti-epileptic medications are typically not 
enzyme inducing and therefore limit the risks of adverse drug-drug interactions and eligibility 
for participation in early phase clinical trials.  
 
Additionally, there is specific concern regarding the use of immunotherapeutics.  A major 
impediment to effective in vivo activity in patients with primary brain tumours is the oft-
needed baseline use of corticosteroids to control intra-cerebral edema.  It is well known that 
corticosteroids diminish immune activity and therefore their presence at baseline could 
impair the robustness of any anti-tumour immune response.  In this respect, combination 
strategies with drugs such as bevacizumab which may have a steroid sparing effect (118) 
may augment anti-tumour immunity.  Moreover, if a response was nevertheless to occur, 
there remains concern that tumour flare may present with mass effect like symptoms, which 
can be quite significant in a patient population already suffering from cerebral edema, or 
auto-immune neurotoxicity. Caution must continue, though it is reassuring that most reported 
studies of checkpoint inhibitors in glioblastoma to date have not shown an adverse event 
profile substantially dissimilar to other solid tumours which mitigates the latter point (8, 119).   
 
Finally, although the various immune combination strategies described in this review hold 
promise due to their underlying biological rationale, implementation of any of these 
strategies needs to take into account the cost of these technologies with a keen focus on the 
ultimate value delivered to be patients (120). 
 
Conclusion 
In conclusion, despite the disappointing results of single agent immunotherapeutics to date, 
there remain reasons to be not only be optimistic, but excited. Understanding the CNS 
cancer immunity cycle provides a suitable framework upon which the various approaches 
and challenges to CNS drug development can be expounded and will be the foundation for 
the development of rational combination strategies to improve patient outcomes in this 
disease.   
  
Figure legends  
Figure 1: The afferent and efferent arms of the CNS immune system 
Dashed line indicates the blood-brain-barrier. Lymphatics are shown in green, and 
vasculature in red. Antigen release triggers recognition of antigens by antigen presenting 
cells, which are channelled via CNS lymphatics to the cervical lymph nodes.  Antigen 
presentation and T cell priming occur peripherally in the cervical lymph nodes before 
trafficking back to the CNS to recognise and kill tumour cells.  
 
Figure 2: The Cancer-Immunity Cycle in CNS malignancies 
T lymphocytes are shown in purple, with CAR-T modified T lymphocytes highlighted with a 
glow. The orange half of the circle marks out steps that can be targeted systemically, while 
the purple indicates steps that require intra-cranial delivery/mode of action. Abbreviations: 
CAR Chimeric antigen receptors; RT radiotherapy; CTLA-4 cytotoxic T-lymphocyte-
associated protein 4; PD-1 Programmed cell death protein 1; PD-L1 Programmed death-
ligand 1; IDO Indoleamine-pyrrole 2,3-dioxygenase; TGF-b Transforming growth factor beta 
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